Autologous serum eye drops for the treatment of dry eye diseases

Takashi Kojima, Akihiro Higuchi, Eiki Goto, Yukihiro Matsumoto, Murat Dogru, Kazuo Tsubota

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Conventional treatment of dry eye mainly consists of the use of preservative-free artificial eye drops and punctal occlusion. None of the commercially available artificial tear preparations include essential tear components such as epidermal growth factor, hepatocyte growth factor, fibronectin, neurotrophic growth factor, and vitamin A-all of which have been shown to play important roles in the maintenance of a healthy ocular surface epithelial milieu. We reported previously that autologous serum (AS) eye drops contain these essential factors and that AS eye drops are beneficial in the treatment of ocular surface diseases such as persistent epithelial defects, superior limbic keratoconjunctivitis, keratoconjunctivitis sicca, and neurotrophic keratopathy. However, there is some controversy regarding the efficacy of AS treatment. We demonstrated that this modality is more effective than artificial tears in a randomized control study. In in vivo and in vitro experiments, AS eye drops showed marked suppression of apoptosis in the conjunctival and corneal epithelium. Albumin, the major protein in serum, improved ocular surface damage in vivo and rescued apoptosis after serum deprivation in vitro. The biological background of AS eye drops and previous clinical studies of these medications for the treatment of dry eye are discussed.

Original languageEnglish
JournalCornea
Volume27
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2008 Sep

Fingerprint

Eye Diseases
Ophthalmic Solutions
Serum
Artificial Eye
Keratoconjunctivitis Sicca
Apoptosis
Keratoconjunctivitis
Corneal Epithelium
Hepatocyte Growth Factor
Nerve Growth Factors
Vitamin A
Tears
Fibronectins
Epidermal Growth Factor
Blood Proteins
Albumins
Intercellular Signaling Peptides and Proteins
Maintenance

Keywords

  • Autologous serum
  • Dry eye
  • Eye drops

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Kojima, T., Higuchi, A., Goto, E., Matsumoto, Y., Dogru, M., & Tsubota, K. (2008). Autologous serum eye drops for the treatment of dry eye diseases. Cornea, 27(SUPPL. 1). https://doi.org/10.1097/ICO.0b013e31817f3a0e

Autologous serum eye drops for the treatment of dry eye diseases. / Kojima, Takashi; Higuchi, Akihiro; Goto, Eiki; Matsumoto, Yukihiro; Dogru, Murat; Tsubota, Kazuo.

In: Cornea, Vol. 27, No. SUPPL. 1, 09.2008.

Research output: Contribution to journalArticle

Kojima, T, Higuchi, A, Goto, E, Matsumoto, Y, Dogru, M & Tsubota, K 2008, 'Autologous serum eye drops for the treatment of dry eye diseases', Cornea, vol. 27, no. SUPPL. 1. https://doi.org/10.1097/ICO.0b013e31817f3a0e
Kojima, Takashi ; Higuchi, Akihiro ; Goto, Eiki ; Matsumoto, Yukihiro ; Dogru, Murat ; Tsubota, Kazuo. / Autologous serum eye drops for the treatment of dry eye diseases. In: Cornea. 2008 ; Vol. 27, No. SUPPL. 1.
@article{60bb258b20124272bc334890639cb5c2,
title = "Autologous serum eye drops for the treatment of dry eye diseases",
abstract = "Conventional treatment of dry eye mainly consists of the use of preservative-free artificial eye drops and punctal occlusion. None of the commercially available artificial tear preparations include essential tear components such as epidermal growth factor, hepatocyte growth factor, fibronectin, neurotrophic growth factor, and vitamin A-all of which have been shown to play important roles in the maintenance of a healthy ocular surface epithelial milieu. We reported previously that autologous serum (AS) eye drops contain these essential factors and that AS eye drops are beneficial in the treatment of ocular surface diseases such as persistent epithelial defects, superior limbic keratoconjunctivitis, keratoconjunctivitis sicca, and neurotrophic keratopathy. However, there is some controversy regarding the efficacy of AS treatment. We demonstrated that this modality is more effective than artificial tears in a randomized control study. In in vivo and in vitro experiments, AS eye drops showed marked suppression of apoptosis in the conjunctival and corneal epithelium. Albumin, the major protein in serum, improved ocular surface damage in vivo and rescued apoptosis after serum deprivation in vitro. The biological background of AS eye drops and previous clinical studies of these medications for the treatment of dry eye are discussed.",
keywords = "Autologous serum, Dry eye, Eye drops",
author = "Takashi Kojima and Akihiro Higuchi and Eiki Goto and Yukihiro Matsumoto and Murat Dogru and Kazuo Tsubota",
year = "2008",
month = "9",
doi = "10.1097/ICO.0b013e31817f3a0e",
language = "English",
volume = "27",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Autologous serum eye drops for the treatment of dry eye diseases

AU - Kojima, Takashi

AU - Higuchi, Akihiro

AU - Goto, Eiki

AU - Matsumoto, Yukihiro

AU - Dogru, Murat

AU - Tsubota, Kazuo

PY - 2008/9

Y1 - 2008/9

N2 - Conventional treatment of dry eye mainly consists of the use of preservative-free artificial eye drops and punctal occlusion. None of the commercially available artificial tear preparations include essential tear components such as epidermal growth factor, hepatocyte growth factor, fibronectin, neurotrophic growth factor, and vitamin A-all of which have been shown to play important roles in the maintenance of a healthy ocular surface epithelial milieu. We reported previously that autologous serum (AS) eye drops contain these essential factors and that AS eye drops are beneficial in the treatment of ocular surface diseases such as persistent epithelial defects, superior limbic keratoconjunctivitis, keratoconjunctivitis sicca, and neurotrophic keratopathy. However, there is some controversy regarding the efficacy of AS treatment. We demonstrated that this modality is more effective than artificial tears in a randomized control study. In in vivo and in vitro experiments, AS eye drops showed marked suppression of apoptosis in the conjunctival and corneal epithelium. Albumin, the major protein in serum, improved ocular surface damage in vivo and rescued apoptosis after serum deprivation in vitro. The biological background of AS eye drops and previous clinical studies of these medications for the treatment of dry eye are discussed.

AB - Conventional treatment of dry eye mainly consists of the use of preservative-free artificial eye drops and punctal occlusion. None of the commercially available artificial tear preparations include essential tear components such as epidermal growth factor, hepatocyte growth factor, fibronectin, neurotrophic growth factor, and vitamin A-all of which have been shown to play important roles in the maintenance of a healthy ocular surface epithelial milieu. We reported previously that autologous serum (AS) eye drops contain these essential factors and that AS eye drops are beneficial in the treatment of ocular surface diseases such as persistent epithelial defects, superior limbic keratoconjunctivitis, keratoconjunctivitis sicca, and neurotrophic keratopathy. However, there is some controversy regarding the efficacy of AS treatment. We demonstrated that this modality is more effective than artificial tears in a randomized control study. In in vivo and in vitro experiments, AS eye drops showed marked suppression of apoptosis in the conjunctival and corneal epithelium. Albumin, the major protein in serum, improved ocular surface damage in vivo and rescued apoptosis after serum deprivation in vitro. The biological background of AS eye drops and previous clinical studies of these medications for the treatment of dry eye are discussed.

KW - Autologous serum

KW - Dry eye

KW - Eye drops

UR - http://www.scopus.com/inward/record.url?scp=58149260591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149260591&partnerID=8YFLogxK

U2 - 10.1097/ICO.0b013e31817f3a0e

DO - 10.1097/ICO.0b013e31817f3a0e

M3 - Article

C2 - 18813071

AN - SCOPUS:58149260591

VL - 27

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - SUPPL. 1

ER -